Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
120 words
An active principle effective for control of the T-system of immunity, said active principle being obtained by removing thermolabile proteins from a solution of homogenized thymus gland tissue in a sodium chloride solution, precipitating proteins and peptides from the solution, dissolving the same in a solvent therefor, salting out the peptides from the solution, dissolving the peptides, subjecting the resulting solution to ultrafiltration, and subjecting the resulting ultrafiltrate to gel chromatography, and said active principle consisting of polypeptides with a molecular mass of from 1,500 to 6,000 Dalton, having the maximum of absorption in UV-light as 208 and 275 nm and the electrophoretic mobility in a polyacrylamide gel relative to bromophenol blue of: 0.062-0.102; 0.156-0.236; 0.354-0.374; 0.382-0.422; 0.432-0.472; 0.485-0.545; 0.850-0.930.
Claim 2
Dependent Claim
120 words
An active principle effective for control of the T-system of immunity, said active principle being obtained by removing thermolabile proteins from a solution of homogenized thymus gland tissue in a sodium chloride solution, precipitating proteins and peptides from the solution, dissolving the same in a solvent therefor, salting out the peptides from the solution, dissolving the peptides, subjecting the resulting solution to ultrafiltration, and subjecting the resulting ultrafiltrate to gel chromatography, and said active principle consisting of polypeptides with a molecular mass of from 1,500 to 6,000 Dalton, having the maximum of absorption in UV-light as 208 and 275 nm and the electrophoretic mobility in a polyacrylamide gel relative to bromophenol blue of: 0.062-0.102; 0.156-0.236; 0.354-0.374; 0.382-0.422; 0.432-0.472; 0.485-0.545; 0.850-0.930.
Claim 3
Dependent Claim
16 words
A preparation according to claim 1, wherein as the pharmaceutical vehicle a physiological solution is used.
Claim 4
Dependent Claim
16 words
A preparation according to claim 2, wherein the physiological solution is a 0.14 M NaCl solution.
Claim 5
Dependent Claim
21 words
A preparation according to claim 1, wherein the content of the active principle is about 100 to 200 μg/ml for injections.
Claim 6
Dependent Claim
264 words
A method for producing the active principle of claim 1 for control of the T-system of immunity, which comprises: (1) homogenizing a thymus gland tissue in a sodium chloride solution; (2) keeping the homogenizate for 12 to 16 hours at a temperature of from 2° to 6° C.; (3) removing the residue from the homogenizate; (4) heating the remaining solution to a temperature within the range of from 70° to 90° C. to from a residue of thermolabile protein components; (5) removing the thermolabile proteins from the solution; (6) precipitating proteins and peptides from the solution; (7) dissolving the thus precipitated proteins and peptides in a solvent therefor; (8) salting-out the peptides from the solution in three stages, the first being conducted in a 20-30%, by saturation, solution of ammonium sulphate at a pH of from 6.9 to 7.1, the second in a 45-55%, by saturation, solution of ammonium sulphate at a pH of from 3.9 to 4.1, and the third in a 45-55%, by saturation, solution of ammonium sulphate at a pH of from 4.5 to 6.0; (9) dissolving the resulting residue of peptides; (10) subjecting the formed solution to ultrafiltration through a membrane with a rated retention limit relative to globular proteins of from 12,000 to 30,000 Dalton; (11) subjecting the obtained ultrafiltrate to gel-chromatography to separate the peptides with a molecular mass of from 1,500 to 6,000 Dalton in a buffer solution at a pH of from 6.8 to 8.2 and an ionic strength of from 0.1 to 0.4 M; (12) desalting the separated peptides and subjecting the same to lyophilization.
Claim 7
Dependent Claim
35 words
The method for producing the active principle according to claim 5, wherein salting-out at the stage (8) is effected at a concentration of proteins and peptides in the solution of from 15 to 25 mg/ml.
Claim 8
Dependent Claim
30 words
The method for producing the active principle according to claim 5, wherein the homogenate in stage (2) is kept at the ratio between the solid and liquid portions of 1:3.
Claim 9
Dependent Claim
28 words
The method for producing the active principle according to claim 5, wherein gel-chromatography of peptides in stage (11) is effected in a buffer solution containing KCl or NaCl.
Claim 10
Dependent Claim
20 words
A preparation comprising an effective amount of the T-system immunity active principle of claim 1 and a pharmaceutical vehicle therefor.